LearnGlossaryMarketStocksSuperinvestorsSign in

ALT

Altimmune, Inc.

Healthcare · $651M market cap

Verdict

We can't put a fair value on ALT right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-22.9% a year✗
Sales growth-16.1% a year✗
Free cash flow growth—?
Return on invested capital-54.5%✗

Follow ALT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds ALT. In Q2 2026, 1 opened a position. Who we track

Viking Global Investors

Viking Global Investors · as of Q2 2026

$20.4M

6,700,000 shares

Moves in Q2 2026

New position: Viking Global Investors

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works